Earnings results for Orchard Therapeutics (NASDAQ:ORTX)
Orchard Therapeutics plc is estimated to report earnings on 03/04/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.3. The reported EPS for the same quarter last year was $-0.46.
Orchard Therapeutics last released its quarterly earnings data on March 2nd, 2021. The reported ($0.34) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.34). Orchard Therapeutics has generated ($1.75) earnings per share over the last year. Orchard Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, March 4th, 2021 based off prior year’s report dates.
Analyst Opinion on Orchard Therapeutics (NASDAQ:ORTX)
4 Wall Street analysts have issued ratings and price targets for Orchard Therapeutics in the last 12 months. Their average twelve-month price target is $14.75, predicting that the stock has a possible upside of 102.61%. The high price target for ORTX is $16.00 and the low price target for ORTX is $12.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Orchard Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $14.75, Orchard Therapeutics has a forecasted upside of 102.6% from its current price of $7.28. Orchard Therapeutics has only been the subject of 3 research reports in the past 90 days.
Dividend Strength: Orchard Therapeutics (NASDAQ:ORTX)
Orchard Therapeutics does not currently pay a dividend. Orchard Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Orchard Therapeutics (NASDAQ:ORTX)
In the past three months, Orchard Therapeutics insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,277,660.00 in company stock. Only 4.20% of the stock of Orchard Therapeutics is held by insiders. 66.55% of the stock of Orchard Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Orchard Therapeutics (NASDAQ:ORTX
Earnings for Orchard Therapeutics are expected to grow in the coming year, from ($1.47) to ($1.32) per share. The P/E ratio of Orchard Therapeutics is -4.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Orchard Therapeutics is -4.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Orchard Therapeutics has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
More latest stories: here